Rohit Thummalapalli

OncoDaily

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary

Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

April, 2025

Rohit Thummalapalli

Apr 26, 2025, 16:35 | Science

Federica Pecci: Factors linked to prolonged disease control after stopping ICIs for irAEs in advanced NSCLC

Federica Pecci, Research Fellow at Dana-Farber Cancer Institute, shared a post on X about a…

Sep 24, 2024, 13:32 | Insight

Jarushka Naidoo: Stage III ALK+ NSCLC - consolidation ALK TKI vs Durvalumab vs Observation

Jarushka Naidoo shared on X: "Stage III ALK+ NSCLC: consolidation ALK Tyrosine Kinase Inhibitors versus…

Feb 7, 2024, 12:46 | Blog

Amin Nassar presents the results of a multicenter retrospective cohort for osimertinib and durvalumab in unresectable EGFR-mutant NSCLC

Amin Nassar, Hematology/Oncology Fellow at Yale University, shared a post on X/Twitter: "1. Pumped to…

All: 3 Posts: 1 - 100

'

10 Caring Notes from Pope Francis on Healthcare

'

FDA Approves Penpulimab for Recurrent or Metastatic Non-Keratinizing Nasopharyngeal Carcinoma

'

Senate President Passes Away After Brave Battle with Cancer: Dominick J. Ruggerio

'

Where to Study to Become ASCO President: 2025 Institutional Rankings

'

Yelak Biru: UK grants first approval for Blenrep in multiple myeloma

Special Coverage

Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
ESMO 2024 Congress
September 13-17, 2024
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023